QUANTUM X LABS INC. annual report, FY2014

Filing summary

Issuer and period: The supplied filing is Zaxis International Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 12, 2015—not a filing identified as Quantum X Labs Inc. The period is the full fiscal year; separate fourth-quarter results are not provided.

Business context and reporting period

Zaxis reported no current business operations and described itself as a shell company pursuing a business combination. Its historical electrophoresis-products business had ceased operations. In December 2014, Zaxis entered a non-binding MOU to pursue a reverse merger with Emerald Medical Applications Ltd., which develops early-stage melanoma detection and diagnosis technology. The proposed transaction remained subject to a definitive agreement and other conditions.

Financial results and liquidity

MetricFY 2014FY 2013
Revenue$0$0
General and administrative expense$28,125$41,200
Interest expense$20,745$10,200
Debt discount amortization$125,000$0
Net loss$173,870$51,400
Reported operating cash flow$1,000($5,950)

G&A declined 32%, mainly because of lower compensation expense. Interest expense increased 103%, which management attributed mainly to interest on advances converted into convertible notes. The 2014 net loss included $125,000 of non-cash debt-discount amortization, accelerated when convertible notes converted to shares. Gross and operating margins are not meaningful because the company had no revenue.

At December 31, 2014, cash was $1,000, current assets were $1,000, current liabilities were $163,784, and total liabilities were $186,159, including $22,375 of long-term notes payable. Working capital was negative $162,784. Current liabilities included $120,979 of advances payable and $35,305 of accrued interest. The filing says the company relied on management and affiliated parties for interim funding; it had no material cash resources. The auditors issued an unqualified opinion but included a going-concern explanatory paragraph citing substantial doubt about the company’s ability to continue.

Material changes, outlook, and risks

  • Five holders converted $125,000 of notes into 4,125,000 shares during 2014; $35,295 of related accrued interest remained unpaid at year-end. The filing also describes $120,979 of advances as transferred to an unrelated party and $22,375 as converted into a nonconvertible note.
  • The company’s leadership changed twice in late 2014: Jehuda Maimon was appointed and then removed after the Artsys reverse-merger proposal was abandoned; Liron Carmel became CEO, CFO, and sole director. Oded Gilboa was appointed CFO in February 2015.
  • The Emerald MOU contemplated an $800,000 third-party raise. Emerald holders were to receive 45% of fully diluted shares after closing, plus up to 21% in milestone-based tranches. The transaction was not assured, and management said it might pursue an alternative combination.
  • After year-end, Zaxis agreed to lend Emerald $90,000 and reported issuing 750,000 restricted units, each comprising one share and one warrant, at a post-reverse-split price of $0.40 per unit. These transactions do not establish that the proposed merger closed.
  • Management warned that additional financing was necessary to continue as a going concern. Risks include inability to secure funding or complete a merger, dilution or control changes from new securities, dependence on a single future business, conflicts of interest, limited trading liquidity, and penny-stock restrictions. The company did not expect to pay dividends.
  • Disclosure controls and internal control over financial reporting were reported ineffective because of a lack of segregation of duties. The filing reported no legal proceedings, contractual obligations, or off-balance-sheet arrangements.

Important facts for investors to verify

  • Confirm the issuer’s identity: the filing names Zaxis International Inc., while the request metadata names Quantum X Labs Inc.
  • Check subsequent SEC filings for whether the Emerald definitive agreement, $800,000 financing, and reverse merger were completed, and review the terms and status of the $90,000 loan.
  • Reconcile the share counts and capital structure, including the reported year-end shares, January 2015 reverse split, subsequent unit issuance, and March 2015 outstanding-share figures.
  • Verify the composition, maturity, interest, and repayment status of year-end liabilities and the unpaid accrued interest.
  • Review funding commitments and cash needs in light of the going-concern warning, and assess whether internal-control deficiencies were remediated.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.